Aclarion, Inc. (ACON) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated March 6, 2025, reports on events occurring on March 5, 2025. Aclarion, Inc., a Delaware corporation, held a Special Meeting of Stockholders to vote on critical corporate governance and capital structure proposals. The meeting was originally scheduled for February 28, 2025, but was adjourned and reconvened on March 5, 2025.
Key Financial Metrics
The filing does not provide specific financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on the results of the stockholder vote. As of the record date (January 6, 2025), there were 20,626,124 shares of common stock issued and outstanding (prior to a 1-for-35 reverse stock split executed on January 30, 2025).
Material Changes and Voting Results
Approximately 42% of eligible votes were represented at the meeting, constituting a quorum. All three proposals presented to stockholders were approved:
- The Issuance Proposal: Approved to comply with Nasdaq Listing Rule 5635(d), authorizing the full issuance of common stock upon exercise of Series A and Series B Warrants.
- Votes For: 3,750,201
- Votes Against: 383,538
- Abstentions: 6,225
- The Charter Amendment Proposal: Approved to grant the Board discretionary authority to increase authorized common stock from 200,000,000 to 300,000,000 shares within one year.
- Votes For: 7,008,009
- Votes Against: 1,622,299
- Abstentions: 26,715
- The Adjournment Proposal: Approved to allow the Company to adjourn the meeting if necessary to solicit further proxies.
- Votes For: 7,425,910
- Votes Against: 1,104,548
- Abstentions: 126,563
Guidance, Outlook, and Risks
The filing contains no management commentary regarding financial guidance, future outlook, or specific risk factors beyond the context of the voting proposals. The primary contingency addressed was the need for stockholder approval to list the shares issuable upon warrant exercise on the Nasdaq Stock Market.
Key Facts for Investor Verification
- Verify the impact of the approved warrant issuance on potential future dilution.
- Confirm the timing and execution of the authorized increase in common stock from 200 million to 300 million shares.
- Review the definitive proxy statement filed on February 3, 2025, for detailed terms of the Series A and Series B Warrants.
- Note the low participation rate (42%) at the Special Meeting.